keyword
https://read.qxmd.com/read/38418597/-palliative-surgery-for-metastatic-prostate-cancer
#21
REVIEW
Axel Heidenreich, Christian Bach, David Pfister
Androgen deprivation in combination with novel hormonal agents, docetaxel, or in combination with abiraterone/prednisone plus docetaxel or darolutamid plus docetaxel represent the standard therapeutic approach in metastatic hormone-sensitive prostate cancer (mHSPC). Patients with low-risk prostate cancer also benefit from additional radiation therapy or radical prostatectomy in terms of progression-free and overall survival. Despite favorable response rates, basically all patients will develop castration resistant prostate cancer (CRPC) within 2...
February 28, 2024: Urologie
https://read.qxmd.com/read/38410613/equivalent-prognosis-with-no-lymph-node-metastasis-to-pathological-complete-remission-in-patients-with-localized-advanced-esophageal-cancer-after-neoadjuvant-triplet-chemotherapy-with-docetaxel-cisplatin-and-5-fluorouracil-followed-by-curative-surgery-a-single
#22
JOURNAL ARTICLE
Takashi Chinen, Hironori Yamaguchi, Hideyuki Ohzawa, Shiro Matsumoto, Kentaro Kurashina, Shin Saito, Yoshinori Hosoya, Hirofumi Fujii, Joji Kitayama, Naohiro Sata
BACKGROUND: Adjuvant nivolumab therapy has become the standard therapy for patients with localized advanced esophageal cancer with non-pathological complete response after neoadjuvant chemoradiotherapy followed by curative surgery. However, the necessity of this therapy for patients after neoadjuvant chemotherapy (NAC) with docetaxel, cisplatin, and 5-fluorouracil (DCF) regimen followed by surgery is unclear, and the prognosis of grouping based on the presence or absence of pathological tumor and lymph node findings has not been analyzed...
January 30, 2024: Journal of Thoracic Disease
https://read.qxmd.com/read/38384808/clinical-outcomes-of-atezolizumab-versus-standard-of-care-docetaxel-with-and-without-ramucirumab-in-patients-with-advanced-non-small-cell-lung-cancer-who-received-prior-immunotherapy
#23
JOURNAL ARTICLE
Shenduo Li, Rami Manochakian, Ruqin Chen, Jaydeepbhai Patel, Jyothik Varun Inampudi, Koshiya R Hiren, Yujie Zhao, Yanyan Lou
BACKGROUND: Atezolizumab is superior to docetaxel for patients with advanced non-small-cell lung cancer (NSCLC) who are pretreated with platinum-based chemotherapy based on the POPLAR and OAK trials. However, patients who received prior immunotherapy were excluded from these trials. The standard of care second-line therapy for these patients remains to be docetaxel with or without ramucirumab. The efficacy and safety of atezolizumab as a subsequent therapy in immunotherapy-pretreated patients are unknown...
2024: Frontiers in Oncology
https://read.qxmd.com/read/38367405/integration-of-on-treatment-modified-glasgow-prognostic-score-mgps-to-improve-imaging-based-prediction-of-outcomes-in-patients-with-non-small-cell-lung-cancer-on-immune-checkpoint-inhibition
#24
JOURNAL ARTICLE
Jonas Saal, Tobias Bald, Markus Eckstein, Damian J Ralser, Peter Brossart, Jörg Ellinger, Michael Hölzel, Niklas Klümper
INTRODUCTION: A large number of patients with non-small cell lung cancer (NSCLC) on immune checkpoint inhibition (ICI) achieve stable disease (SD) as the best overall response, which is associated with heterogeneous outcomes. In this context, complementary biomarkers that improve outcome prediction are needed. We have recently demonstrated that measuring the on-treatment modified Glasgow prognostic score (mGPS), which is based on the two serum markers C-reactive protein (CRP) and albumin, can improve outcome prediction complementary to radiological staging in metastatic renal cell carcinoma...
February 15, 2024: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/38361751/circthsd4-promotes-the-malignancy-and-docetaxel-dtx-resistance-in-prostate-cancer-by-regulating-mir-203-hmga2-axis
#25
JOURNAL ARTICLE
Jianyun Xie, Linjie Lu, Jiali Zhang, Qirui Li, Weidong Chen
OBJECTIVE: Circular ribose nucleic acids (circRNAs) are implicated in tumor progression and drug resistance of prostate cancer (PCa). The current work explored the function of circ_0005203 (circTHSD4) in the malignancy and docetaxel (DTX) resistance of PCa. METHODS: circTHSD4 expression within PCa as well as matched non-carcinoma samples was measured through real-time reverse transcription-quantitative polymerase chain reaction (RT-qPCR). In addition, a subcellular fraction assay was conducted to determine circTHSD4 subcellular localization within PCa cells...
2024: Oncology Research
https://read.qxmd.com/read/38360906/prophylactic-pegfilgrastim-reduces-febrile-neutropenia-in-ramucirumab-plus-docetaxel-after-chemoimmunotherapy-in-advanced-nsclc-post-hoc-analysis-from-nej051
#26
JOURNAL ARTICLE
Keita Miura, Ou Yamaguchi, Keita Mori, Atsushi Nakamura, Motohiro Tamiya, Tomohiro Oba, Noriko Yanagitani, Hideaki Mizutani, Takashi Ninomiya, Tomosue Kajiwara, Kentaro Ito, Akihiko Miyanaga, Daisuke Arai, Hiroaki Kodama, Kunihiko Kobayashi, Kyoichi Kaira
Ramucirumab plus docetaxel (RD) can cause febrile neutropenia (FN), which frequently requires the prophylactic administration of pegfilgrastim. However, the effects of prophylactic pegfilgrastim on FN prevention, therapeutic efficacy, and prognosis after RD have not been fully evaluated in patients with advanced non-small-cell lung cancer (NSCLC). Two hundred and eighty-eight patients with advanced NSCLC who received RD as second-line therapy after platinum-based chemotherapy plus PD-1 blockade were included...
February 15, 2024: Scientific Reports
https://read.qxmd.com/read/38354183/novel-hormonal-therapy-versus-standard-of-care-a-registry-based-comparative-effectiveness-evaluation-for-mcrpc-patients
#27
JOURNAL ARTICLE
Paulina Jonéus, Per Johansson, Sophie Langenskiöld
BACKGROUND: This paper presents results from one of the few comparative effectiveness evaluations of novel antiandrogen medications (NHT) against standard of care (SoC) for patients suffering from metastatic castrate-resistant prostate cancer (mCRPC). METHODS: The design and the analysis are published in a protocol before accessing outcome data. Two groups of patients are balanced on hundreds of important covariates measured before the prostate cancer diagnosis and up to the date of the prescription...
2024: PloS One
https://read.qxmd.com/read/38353907/effectiveness-and-safety-of-primary-prophylaxis-with-g-csf-for-lung-cancer-a-systematic-review-and-meta-analysis-to-develop-clinical-practice-guidelines-for-the-use-of-g-csf-2022
#28
JOURNAL ARTICLE
Eiki Ichihara, Nobuaki Ochi, Go Makimoto, Kenichiro Kudo, Daijiro Harada, Yukinori Ozaki, Hiroshi Nishio, Kenji Tsuchihashi, Yuji Miura, Makoto Endo, Shingo Yano, Dai Maruyama, Tetsuhiro Yoshinami, Nobuyuki Susumu, Munetaka Takekuma, Takashi Motohashi, Mamoru Ito, Eishi Baba, Keita Uchino, Takahiro Kimura, Yutaro Kamiyama, Shinji Nakao, Shinobu Tamura, Hitomi Nishimoto, Yasuhisa Kato, Atsushi Sato, Toshimi Takano, Toshio Kubo
BACKGROUND: Granulocyte colony-stimulating factor (G-CSF) is commonly administered to cancer patients undergoing myelosuppressive chemotherapy, especially when incidence rate of febrile neutropenia (FN) surpasses 20%. While primary prophylaxis with G-CSF has been proven effective in preventing FN in patients with cancer, there is limited evidence regarding its efficacy in specifically, lung cancer. Our systematic review focused on the efficacy of G-CSF primary prophylaxis in lung cancer...
February 14, 2024: International Journal of Clinical Oncology
https://read.qxmd.com/read/38347114/prognostic-and-predictive-analyses-of-circulating-plasma-biomarkers-in-men-with-metastatic-castration-resistant-prostate-cancer-treated-with-docetaxel-prednisone-with-or-without-bevacizumab
#29
JOURNAL ARTICLE
Andrew B Nixon, Yingmiao Liu, Qian Yang, Bin Luo, Mark D Starr, John C Brady, Wm Kevin Kelly, Himisha Beltran, Michael J Morris, Daniel J George, Andrew J Armstrong, Susan Halabi
BACKGROUND: CALGB 90401 (Alliance) was a phase III trial of 1050 patients with metastatic castration-resistant prostate cancer (mCRPC) comparing docetaxel, prednisone, bevacizumab (DP+B) versus DP alone. While this trial did not show an improvement in overall survival (OS), there were improved intermediate outcomes suggesting that subsets of men may derive benefit from this combination. The purpose of this analysis was to identify prognostic and predictive biomarkers associated with OS and progression-free survival (PFS) benefit from DP+B...
February 12, 2024: Prostate Cancer and Prostatic Diseases
https://read.qxmd.com/read/38347041/the-metabolism-related-lncrna-signature-predicts-the-prognosis-of-breast-cancer-patients
#30
JOURNAL ARTICLE
Xin Ge, Shu Lei, Panliang Wang, Wenkang Wang, Wendong Wang
Long non-coding RNAs (lncRNAs) involved in metabolism are recognized as significant factors in breast cancer (BC) progression. We constructed a novel prognostic signature for BC using metabolism-related lncRNAs and investigated their underlying mechanisms. The training and validation cohorts were established from BC patients acquired from two public sources: The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO). The prognostic signature of metabolism-related lncRNAs was constructed using the least absolute shrinkage and selection operator (LASSO) cox regression analysis...
February 12, 2024: Scientific Reports
https://read.qxmd.com/read/38346967/exploiting-epigenetic-targets-to-overcome-taxane-resistance-in-prostate-cancer
#31
JOURNAL ARTICLE
Buse Cevatemre, Ipek Bulut, Beyza Dedeoglu, Arda Isiklar, Hamzah Syed, Ozlem Yedier Bayram, Tugba Bagci-Onder, Ceyda Acilan
The development of taxane resistance remains a major challenge for castration resistant prostate cancer (CR-PCa), despite the effectiveness of taxanes in prolonging patient survival. To uncover novel targets, we performed an epigenetic drug screen on taxane (docetaxel and cabazitaxel) resistant CR-PCa cells. We identified BRPF reader proteins, along with several epigenetic groups (CBP/p300, Menin-MLL, PRMT5 and SIRT1) that act as targets effectively reversing the resistance mediated by ABCB1. Targeting BRPFs specifically resulted in the resensitization of resistant cells, while no such effect was observed on the sensitive compartment...
February 12, 2024: Cell Death & Disease
https://read.qxmd.com/read/38337100/assessing-the-efficacy-of-anti-cancer-drugs-on-organoid-models-derived-from-prostate-cancer
#32
JOURNAL ARTICLE
M O Silkina, A V Razumovskaya, S V Nikulin, A G Tonevitsky, B Ya Alekseev
It was proven that tumor organoids effectively mirror the phenotypic and genetic traits of the original biomaterial. It was reported that outcomes from drug testing in organoid cultures can accurately represent the clinical response observed in patients. In this study, an organoid culture was derived from biopsy material of prostate cancer (PC). Subsequently, clinical practice drugs, docetaxel and enzalutamide, were tested on this organoid culture. Various techniques for evaluating the efficacy of drugs in vitro were compared...
February 9, 2024: Doklady. Biochemistry and Biophysics
https://read.qxmd.com/read/38333300/suspected-nut-carcinoma-progressing-on-pembrolizumab-carboplatin-and-paclitaxel-as-first-line-treatment-a-case-report
#33
Ahmed Badran, Saad Salman Ali, Tarek Ziad Arabi, Abdulaziz Mohammed Alaklabi, Hytham Mubarak Abdalla, Shamayel Mohammed, Belal Nedal Sabbah, Mahmoud A Elshenawy, Jean Paul Atallah
INTRODUCTION AND IMPORTANCE: NUT carcinoma of the thorax is an extremely rare neoplasm characterized by a translocation between the NUT M1 gene and members of the bromodomain genetic family. Due to the rarity of the neoplasm, standardized treatment guidelines have not yet been established. Several chemotherapeutic agents have been used with limited success, due to the rapid development of resistance to treatment. Pembrolizumab, an anti-programmed-death-1 antibody, has become increasingly used in non-small-cell lung carcinomas...
February 2024: Annals of Medicine and Surgery
https://read.qxmd.com/read/38329737/induction-chemotherapy-followed-by-radiotherapy-vs-chemoradiotherapy-in-nasopharyngeal-carcinoma-a-randomized-clinical-trial
#34
JOURNAL ARTICLE
Jinxuan Dai, Bin Zhang, Yixin Su, Yufei Pan, Zhenkai Ye, Rui Cai, Guanjie Qin, Xiangyun Kong, Yunyan Mo, Rongjun Zhang, Zhengchun Liu, Yuan Xie, Xiaolan Ruan, Wei Jiang
IMPORTANCE: Induction chemotherapy plus concurrent chemoradiotherapy is recommended for locoregionally advanced nasopharyngeal carcinoma but is associated with higher rates of acute toxic effects and low compliance. Evidence on de-escalating treatment intensity after induction chemotherapy is limited. OBJECTIVE: To assess if radiotherapy was noninferior to chemoradiotherapy after induction chemotherapy for locoregionally advanced nasopharyngeal carcinoma. DESIGN, SETTING, AND PARTICIPANTS: From April 2015 to March 2018, a multicenter, open-label, randomized, noninferiority, phase 3 trial was conducted at 5 Chinese hospitals...
February 8, 2024: JAMA Oncology
https://read.qxmd.com/read/38321088/pan-caner-analysis-identifies-psma7-as-a-targets-for-amplification-at-20q13-33-in-tumorigenesis
#35
JOURNAL ARTICLE
Guangying Sheng, Fuyu Li, Wen Jin, Kankan Wang
The chromosome 20 long arm (20q) is one of the genomic hotspots where copy number alterations frequently occur in multiple types of tumors. However, it remains elusive which genes are implicated in 20q-related tumorigenesis. Here, by querying TCGA and GEO databases, we observed frequent copy number amplification at 20q and the chromosome subband 20q13.33 was amplificated in multiple cancers. Among those genes at 20q13.33, PSMA7 was found with the strongest correlation with cancers. Further analysis revealed that PSMA7 amplification was the most frequent genetic alteration event conferring adverse prognosis in various cancers...
February 6, 2024: Scientific Reports
https://read.qxmd.com/read/38316286/second-line-treatment-options-in-metastatic-castration-resistant-prostate-cancer-after-progression-on-first-line-androgen-receptor-targeting-therapies-a-systematic-review-and-bayesian-network-analysis
#36
REVIEW
Xingyu Xiong, Shiyu Zhang, Weitao Zheng, Xinyang Liao, Jie Yang, Hang Xu, Siping Hu, Qiang Wei, Lu Yang
OBJECTIVE: To summarize and indirectly compare the efficacy and safety of different second-line systematic therapies after first-line androgen-receptor targeting therapies (ARTs) for biomarker-unselected metastatic castration-resistant prostate cancer (mCRPC) patients. METHODS: Studies published in English up to May 2023 were identified in PubMed, Web of Science and ASCO-GU 2023. Studies accessing the efficacy and safety of second-line systematic therapies after first-line ARTs for biomarker-unselected mCRPC patients were eligible for current systematic review and network meta-analysis (NMA)...
February 3, 2024: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/38302255/optimizing-quality-of-life-integrating-palliative-care-for-patients-with-hand-foot-syndrome-in-oncology-practice
#37
JOURNAL ARTICLE
Divya Sai Vanumu, Praveen Kumar Kodisharapu, Praneeth Suvvari, Basanth Kumar Rayani, Nikhil Pathi, Rohan Tewani, Senthil J Rajappa
Hand-foot syndrome (HFS) emerges as one of the common dermatological side effects associated with anticancer medications such as 5-fluorouracil (5-FU), capecitabine and docetaxel. This condition can be notably debilitating, exerting a predominant impact on the clinical, functional and psychosocial domains of health. With prevalence rates of HFS, ranging from 43% to 71%, there exists an unmet need among palliative care physicians to comprehend this syndrome in addressing physical, psychological dimensions and its integrated management within healthcare...
February 1, 2024: BMJ Supportive & Palliative Care
https://read.qxmd.com/read/38296736/clinical-outcomes-of-patients-with-high-risk-metastatic-hormone-na%C3%A3-ve-prostate-cancer-a-3-year-interim-analysis-of-the-observational-j-rock-study
#38
JOURNAL ARTICLE
Hideaki Miyake, Rikiya Matsumoto, Kiyohide Fujimoto, Atsushi Mizokami, Hirotsugu Uemura, Toshiyuki Kamoto, Satoru Kawakami, Kazuyoshi Nakamura, Shigekatsu Maekawa, Kazuhiro Shibayama, Aki Watanabe, Miku Ito, Yohei Tajima, Hideyasu Matsuyama, Hiroji Uemura
BACKGROUND: Androgen deprivation therapy (ADT), administered alone, as combined androgen blockade (CAB) or as ADT plus androgen receptor signalling inhibitors (ARSIs) or ADT plus docetaxel, is the standard treatment for metastatic hormone-naïve prostate cancer (mHNPC) in Japanese real-world practice. OBJECTIVE: To investigate treatment patterns and clinical outcomes in LATITUDE criteria high-risk mHNPC. DESIGN, SETTING, AND PARTICIPANTS: The longitudinal, multicentre, J-ROCK registry study enrolled patients initiating ADT in Japan after May 2019, and categorised them as cohort 1 (ADT or CAB) or cohort 2 (ADT plus ARSIs or docetaxel)...
January 30, 2024: European Urology Oncology
https://read.qxmd.com/read/38292414/a-comparative-study-evaluating-the-quality-of-life-and-survival-outcomes-in-patients-receiving-chemotherapy-versus-oral-tyrosine-kinase-inhibitor-in-the-third-line-and-beyond-setting-for-advanced-nsclc
#39
JOURNAL ARTICLE
Vanita Noronha, Nandini S Menon, Vijay Maruti Patil, M V Chandrakanth, Sucheta More, Aditya Dhanawat, Oindrila Roy Chowdhary, Ajaykumar Chandrabhan Singh, Supriya Goud, Srushti Shah, Naveen Karuvandan, Kunal Naishadh Jobanputra, Darshit Kalpeshkumar Shah, Minit Jalan Shah, Rupjyoti Sarma, Dhwaniben Patel, Ritam Joarder, Prashant Kumar, Anupa John, Jaspreet Kaur, Saurabh Bagra, Nilendu Purandare, Amit Janu, Abhishek Mahajan, Kumar Prabhash
INTRODUCTION: The outcomes in advanced NSCLC have improved owing to the availability of more effective systemic and improved supportive care. This has increased the number of patients who seek treatment in the third line and beyond setting. We conducted this study to compare the quality of life (QoL), toxicity, and outcomes in patients receiving chemotherapy and EGFR tyrosine kinase inhibitors (TKIs) in this setting. METHODS: In this phase 3, randomized, open-label study, patients with stage III or IV NSCLC with disease progression on at least two prior lines of chemotherapy, with a life expectancy of at least 3 months, without prior EGFR TKI exposure, and stable brain metastases (if any) were included...
January 2024: JTO clinical and research reports
https://read.qxmd.com/read/38269512/durvalumab-and-taxane-family-combination-therapy-enhances-the-antitumoral-effects-for-nsclc-an-in-vitro-study
#40
JOURNAL ARTICLE
Mohammad-Reza Firoozi, Sanam Sadeghi-Mohammadi, Milad Asadi, Najibeh Shekari, Farshad Seyed Nejad, Mostafa Alizade-Harakiyan, Zahra Soleimani, Habib Zarredar
Immunotherapy has lately become the most preferred cancer treatment method, and for non-small cell lung cancer (NSCLC) first-line treatment, there are many immunotherapy options. This study aimed to assess the effectiveness and toxicity of paclitaxel (PTX), docetaxel (DTX) chemotherapy, immune checkpoint inhibitor treatment (durvalumab; DVL), and their combination in NSCLC. A-549 cells were treated with DVL in combination with PTX and DTX (a quarter of the IC50 ) to investigate their anticancer effects on these cells...
January 2024: Cell Biochemistry and Function
keyword
keyword
58392
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.